-+ 0.00%
-+ 0.00%
-+ 0.00%

GlaxoSmithKline announced that in patients with platinum-resistant ovarian cancer, the median progression-free survival with Morez therapy reached 11.1 months. GlaxoSmithKline also announced that in ovarian cancer trials, the objective remission rate confirmed by Moretz therapy was 62%, with a median remission duration of 12.2 months.

Zhitongcaijing·10/24/2026 00:33:05
Listen to the news
GlaxoSmithKline announced that among patients with platinum-resistant ovarian cancer, the median progression-free survival with Morez therapy reached 11.1 months. GlaxoSmithKline also announced that in ovarian cancer trials, the objective remission rate confirmed by Moretz therapy was 62%, with a median remission duration of 12.2 months.